The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
Open accessAbstract
Histone deacetylases (HDACs) affect cell growth at the transcriptional level by regulating the acetylation status of nucleosomal histones. HDAC inhibition induces differentiation and/or apoptosis in transformed cells. We recently showed that HDAC inhibitors, such as suberoylanilide hydroxamic acid (SAHA), potently induce apoptosis of human multiple myeloma (MM) cells. In this study, we focused on MM as a model to study the transcriptional profile of HDAC inhibitor treatment on tumor cells and to address their pathophysiological implications with confirmatory mechanistic and functional assays. We found that MM cells are irreversibly committed to cell death within few hours of incubation with SAHA. The molecular profile of MM cells before their commitment to SAHA-induced cell death is hallmarked by a constellation of antiproliferative and/or proapoptotic molecular events, including down-regulation of transcripts for members of the insulin-like growth factor (IGF)/IGF-1 receptor (IGF-1R) and IL-6 receptor (IL-6R) signaling cascades, antiapoptotic molecules (e.g., caspase inhibitors), oncogenic kinases, DNA synthesis/repair enzymes, and transcription factors (e.g., XBP-1, E2F-1) implicated in MM pathophysiology. Importantly, SAHA treatment suppresses the activity of the proteasome and expression of its subunits, and enhances MM cell sensitivity to proteasome inhibition by bortezomib (PS-341). SAHA also enhances the anti-MM activity of other proapoptotic agents, including dexamethasone, cytotoxic chemotherapy, and thalidomide analogs. These findings highlight the pleiotropic antitumor effects of HDAC inhibition, and provide the framework for future clinical applications of SAHA to improve patient outcome in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
Akiyama, M., Hideshima, T., Hayashi, T., Tai, Y., Mitsiades, C. S., Mitsiades, N., Chauhan, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2002) · PubMed · Cited by 198
Self-citationRetractedThe language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Self-citationStructures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationFused transcript of abl and bcr genes in chronic myelogenous leukaemia
Shtivelman, E., Lifshitz, B., Gale, R. P., & Canaani, E. (1985) · Nature · doi:10.1038/315550a0 · Cited by 1,611
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Self-citationRichon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationRole of the histone deacetylase complex in acute promyelocytic leukaemia
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,062
Nevins, J. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.699 · Cited by 922
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citationMolecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Self-citationMitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1768 · Cited by 697
Self-citationMitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Self-citationKelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Self-citationButler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Self-citationCarter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601
Histone deacetylase inhibitors as new cancer drugs
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531
Self-citationMitsiades, C. S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S. P., Munshi, N. C., Richardson, P. G., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205664 · Cited by 464
Self-citationUbiquitin Conjugation Is Not Required for the Degradation of Oxidized Proteins by Proteasome
Shringarpure, R., Grune, T., Mehlhase, J., & Davies, K. J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206279200 · Cited by 441
Self-citationHideshima, T., Chauhan, D., Schlossman, R., Richardson, P., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204623 · Cited by 394
Self-citationSignaling Network Model of Chromatin
Schreiber, S. L., & Bernstein, B. E. (2002) · Cell · doi:10.1016/s0092-8674(02)01196-0 · Cited by 393
Mariadason, J. M., Corner, G. A., & Augenlicht, L. H. (2000) · PubMed · Cited by 375
Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.11.4079 · Cited by 367
Self-citationSuppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation
Garkavtsev, I., Kazarov, A., Gudkov, A., & Riabowol, K. (1996) · Nature Genetics · doi:10.1038/ng1296-415 · Cited by 300
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
Mitsiades, N., Mitsiades, C. S., Richardson, P. G., McMullan, C., Poulaki, V., Fanourakis, G., Schlossman, R., Chauhan, D., Munshi, N. C., Hideshima, T., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3514 · Cited by 294
Self-citationRole of the F-box protein Skp2 in lymphomagenesis
Latres, E., Chiarle, R., Schulman, B. A., Pavletich, N. P., Pellicer, A., Inghirami, G., & Pagano, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041475098 · Cited by 279
Kalitsis, P., Earle, E., Fowler, K. J., & Choo, K. H. A. (2000) · Genes & Development · doi:10.1101/gad.827500 · Cited by 241
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen
Ridley, R., Xiao, H., Hata, H., Woodliff, J., Epstein, J., & Sanderson, R. (1993) · Blood · doi:10.1182/blood.v81.3.767.767 · Cited by 226
Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma
Seidel, C., Børset, M., Turesson, I., Abildgaard, N., Sundan, A., & e Nordic Myeloma Study Group, A. W. F. T. (1998) · Blood · doi:10.1182/blood.v91.3.806 · Cited by 214
Chauhan, D., Hideshima, T., Rosen, S., Reed, J. C., Kharbanda, S., & Anderson, K. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100074200 · Cited by 202
Self-citationGlick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., & Quaglia, M. P. L. (1999) · PubMed · Cited by 185
Self-citationInterleukin-21 is a growth and survival factor for human myeloma cells
Brenne, A.-T., Baade Ro, T., Waage, A., Sundan, A., Borset, M., & Hjorth-Hansen, H. (2002) · Blood · doi:10.1182/blood.v99.10.3756 · Cited by 168
Ras oncogene mutation in multiple myeloma.
Neri, A., Murphy, J. P., Cro, L., Ferrero, D., Tarella, C., Baldini, L., & Dalla-Favera, R. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1715 · Cited by 164
Murata, T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1071 · Cited by 163
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Anderson, K. C., & Treon, S. P. (2002) · Blood · doi:10.1182/blood.v99.6.2162 · Cited by 159
Self-citationThe biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
Hideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Gupta, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2002) · PubMed · Cited by 155
Self-citationThe Ewing's sarcoma gene product functions as a transcriptional activator.
Rossow, K. L., & Janknecht, R. (2001) · PubMed · Cited by 138
Moalli, P., Pillay, S., Weiner, D., Goldman-Leikin, R. E., & Rosen, S. (1992) · Blood · doi:10.1182/blood.v79.1.213.bloodjournal791213 · Cited by 112
Richon, V. M., Zhou, X., Rifkind, R. A., & Marks, P. A. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0376 · Cited by 97
Self-citationDistinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion
Aalto, Y., El-Rifai, W. M., Vilpo, L. M., Ollila, J., Nagy, B., Vihinen, M., Vilpo, J., & Knuutila, S. (2001) · Leukemia · doi:10.1038/sj.leu.2402282 · Cited by 89
Ng, P. P., Cruz, J. S. D., Sorour, D. N., Stinebaugh, J. M., Shin, S.-U., Shin, D. S., Morrison, S. L., & Penichet, M. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162362999 · Cited by 84
Goruppi, S., Chiaruttini, C., Ruaro, M. E., Varnum, B. C., & Schneider, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.902-915.2001 · Cited by 84
Chauhan, D., Li, G., Auclair, D., Hideshima, T., Richardson, P. G. G., Podar, K., Mitsiades, N., Mitsiades, C. S., Li, C., Kim, R. S., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3146 · Cited by 78
Self-citationSakabe, T., Shinomiya, T., Mori, T., Ariyama, Y., Fukuda, Y., Fujiwara, T., Nakamura, Y., & Inazawa, J. (1999) · PubMed · Cited by 62
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
“…of colon, bladder, kidney, prostate and breast, cultured for up to 48 h with butyrate, TSA, MS-275, vorinostat or FK228 (depsipeptide) using twofold change as the cut-off value (Chambers et al., 2003; Glaser et al., 2003; Mitsiades et al., 2004; Peart et al., 2005; Sasakawa et al., 2005).”
BackgroundMethodInfluentialSelf-citationUbiquitination in disease pathogenesis and treatment
Popovic, D., Vucic, D., & Dikic, I. (2014) · Nature Medicine · doi:10.1038/nm.3739 · Cited by 1,401
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Self-citation
Metadata
- Authors
- Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Richon, V. M., Marks, P. A., & Anderson, K. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-12-26
- Volume
- 101
- Issue
- 2
- Pages
- 540-545
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2149386327
- Cited by
- 531
- References
- 46
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.